# Effects of DPP4 Inhibition on COVID-19

> **NCT04341935** · PHASE4 · WITHDRAWN · sponsor: **University of Miami**

## Conditions studied

- Coronavirus Infection
- Type 2 Diabetes

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Insulin regimen

## Key facts

- **NCT ID:** NCT04341935
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-30
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Logistical challenges amid COVID-19 pandemic and lack of financial support
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04341935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04341935, "Effects of DPP4 Inhibition on COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04341935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*